Advertisement

Clinical Outcomes of Rate vs Rhythm Control for Atrial Fibrillation in Older People: A Systematic Review and Meta-Analysis

  • Laurence Depoorter
  • Liza Sels
  • Mieke Deschodt
  • Bastiaan Van Grootven
  • Lorenz Van der Linden
  • Jos TournoyEmail author
Systematic Review
  • 59 Downloads

Abstract

Background and Objectives

Atrial fibrillation (AF) is highly prevalent in older adults and has been associated with increased morbidity and mortality. To reduce this AF-related morbidity in older adults, antiarrhythmic drugs (AADs) are regularly used for rhythm control, assuming that increasing time in sinus rhythm reduces AF-related morbidity. However, whether AADs can improve clinical outcomes in older adults remains unclear because of the increased risk for adverse drug events compared with rate control. The aim of this study was to determine the impact of rhythm control versus rate control on clinical outcomes in older adults with AF.

Design and Methods

We conducted a systematic review and meta-analysis targeting patients aged ≥65 years with AF and using drugs to control rate or rhythm. Articles that met the following criteria were included: enrolled older patients (sample mean ≥75 years) with AF, compared pharmacological rate versus rhythm control, and reported all-cause mortality, cardiovascular mortality, or ischemic stroke.

Results

Five observational studies were included. In total, 86,926 patients with AF with a mean age ranging from 75 to 92 years were studied. No differences were found between rhythm and rate control for all-cause mortality (odds ratio [OR] 1.11; 95% confidence interval [CI] 0.78–1.59; I2 = 79.6%; n = 28,526; four studies) and cardiovascular mortality (OR 1.09; 95% CI 0.81–1.47; I2 = 0%; n = 2292; two studies). Rhythm control resulted in fewer strokes (OR 0.86; 95% CI 0.80–0.93; I2 = 0%; n = 59,496), although this was mainly determined by one study.

Conclusion

All collected data were observational, which precluded making strong recommendations. Furthermore, all CIs were wide, increasing the uncertainty of the observed effects. As such, evidence was insufficient to recommend rhythm or rate control as the first-line therapy for AF in older adults. As AF is particularly prevalent in older people, more randomized controlled trials are needed in this population.

Notes

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this manuscript.

Conflict of interest

L. Depoorter, L. Sels, M. Deschodt, and B. Van Grootven have no potential conflicts of interest that might be relevant to the contents of this manuscript. L. Van der Linden and J. Tournoy have received lecture or consulting fees from Pfizer, Bristol-Meyers Squibb, Bayer, and Daichii Sankyo.

Supplementary material

40266_2019_722_MOESM1_ESM.pdf (143 kb)
Supplementary file1 (PDF 143 kb)
40266_2019_722_MOESM2_ESM.pdf (101 kb)
Supplementary file2 (PDF 101 kb)

References

  1. 1.
    Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. JAMA. 2001;285(18):2370–5.CrossRefGoogle Scholar
  2. 2.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983–9.CrossRefGoogle Scholar
  3. 3.
    Mavaddat N, Roalfe A, Fletcher K, et al. Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham Atrial Fibrillation Treatment of the Aged Study). Stroke. 2014;45(5):1381–6.CrossRefGoogle Scholar
  4. 4.
    Healey JS, Oldgren J, Ezekowitz M, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet. 2016;388(10050):1161–9.CrossRefGoogle Scholar
  5. 5.
    Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016;37(38):2893–962.CrossRefGoogle Scholar
  6. 6.
    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.CrossRefGoogle Scholar
  7. 7.
    Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.CrossRefGoogle Scholar
  8. 8.
    Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1579–2158158.CrossRefGoogle Scholar
  9. 9.
    Caldeira D, David C, Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis. 2012;105(4):226–38.CrossRefGoogle Scholar
  10. 10.
    Sethi NJ, Feinberg J, Nielsen EE, et al. The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a systematic review with meta-analysis and trial sequential analysis. PLoS O ne. 2017;12(10):1–28.Google Scholar
  11. 11.
    Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–6.CrossRefGoogle Scholar
  12. 12.
    Shariff N, Desai RV, Patel K, et al. Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation. Am J Med. 2013;126(10):887–93.CrossRefGoogle Scholar
  13. 13.
    Wutzler A, von Ulmenstein S, Attanasio P, et al. Treatment of nonagenarians with atrial fibrillation: insights from the Berlin atrial fibrillation (BAF) registry. J Am Med Dir Assoc. 2015;16(11):969–72.CrossRefGoogle Scholar
  14. 14.
    Paciullo F, Proietti M, Bianconi V, et al. Choice and outcomes of rate control versus rhythm control in elderly patients with atrial fibrillation: a report from the REPOSI study. Drugs Aging. 2018;35(4):365–73.CrossRefGoogle Scholar
  15. 15.
    Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med. 2012;172(13):997–1004.CrossRefGoogle Scholar
  16. 16.
    Tsadok MA, Jackevicius CA, Essebag V, et al. Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation. 2012;126(23):2680–7.CrossRefGoogle Scholar
  17. 17.
    Tavernier R, Wolf M, Kataria V, et al. Screening for atrial fibrillation in hospitalised geriatric patients. Heart. 2018;104(7):588–93.CrossRefGoogle Scholar
  18. 18.
    Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–33.CrossRefGoogle Scholar
  19. 19.
    Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834–40.CrossRefGoogle Scholar
  20. 20.
    Roy D, Talajic M, Nattel S, et al. Rythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):1315–23.CrossRefGoogle Scholar
  21. 21.
    Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the strategies of treatment of atrial fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690–6.CrossRefGoogle Scholar
  22. 22.
    Camm AJ, Breithardt G, Crijns H, et al. Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation: RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol. 2011;58(5):493–501.CrossRefGoogle Scholar
  23. 23.
    Noheria A, Shrader P, Piccini JP, et al. Rhythm control versus rate control and clinical outcomes in patients with atrial fibrillation: results from the ORBIT-AF registry. JACC Clin Electrophysiol. 2016;2(2):221–9.CrossRefGoogle Scholar
  24. 24.
    Albina G, De Luca J, Conde D, et al. Atrial fibrillation: an observational study with outpatients. Pacing Clin Electrophysiol. 2014;37(11):1485–91.CrossRefGoogle Scholar
  25. 25.
    Ayan M, Pothineni NV, Siraj A, et al. Cardiac drug therapy-considerations in the elderly. J Geriatr Cardiol. 2016;13(12):992–7.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Shelton RJ, Clark AL, Goode K, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFÉ-II study). Heart. 2009;95(11):924–30.CrossRefGoogle Scholar
  27. 27.
    Ha AC, Breithardt G, Camm AJ, et al. Health-related quality of life in patients with atrial fibrillation treated with rhythm control versus rate control: insights from a prospective international registry (registry on cardiac rhythm disorders assessing the control of atrial fibrillation: RECORD-AF). Circ Cardiovasc Qual Outcomes. 2014;7(6):896–904.CrossRefGoogle Scholar
  28. 28.
    Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the rate control versus electrical cardioversion (RACE) study. J Am Coll Cardiol. 2004;43(2):241–7.CrossRefGoogle Scholar
  29. 29.
    Jenkins LS, Brodsky M, Schron E, et al. Quality of life in atrial fibrillation: the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Am Heart J. 2005;149(1):112–20.CrossRefGoogle Scholar
  30. 30.
    Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342(13):913–20.CrossRefGoogle Scholar
  31. 31.
    Mannucci PM, Nobili A, Pasina L, et al. Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. Intern Emerg Med. 2018;13(8):1191–200.CrossRefGoogle Scholar
  32. 32.
    Franchi C, Antoniazzi S, Proietti M, et al. Appropationess of oral anticoagulation therapy prescription and its associated factors in hospitalized older people with atrial fibrillation. Br J Clin Pharmacol. 2018;84(9):2010–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Geriatric DepartmentUniversity Hospitals LeuvenLeuvenBelgium
  2. 2.Gerontology and Geriatrics, Department of Chronic Diseases, Metabolism and AgeingKU Leuven-University of LeuvenLeuvenBelgium
  3. 3.Nursing Science, Department of Public HealthUniversity of BaselBaselSwitzerland
  4. 4.Research Foundation FlandersBrusselsBelgium
  5. 5.Department of Public Health and Primary CareKU Leuven-University of LeuvenLeuvenBelgium
  6. 6.Pharmacy DepartmentUniversity Hospitals LeuvenLeuvenBelgium
  7. 7.Department of Pharmaceutical and Pharmacological SciencesKU LeuvenLeuvenBelgium

Personalised recommendations